innoscripta helps Allergopharma convert R&D expenses into research funding

Meet Allergopharma

For more than 50 years, Allergopharma has been developing therapeutic solutions for the treatment of allergies. As a subsidiary of the Dermapharm Group, the company's portfolio covers diagnostics and type I allergy therapy, commonly known as allergen immunotherapy. Working in close collaboration with researchers and physicians, Allergopharma delivers effective treatments for allergies.

Allergopharma's strong scientific excellence and entrepreneurial responsibility, along with the vision “we have one goal: curing allergies”, highlight their commitment to providing tailored treatment options to allergy sufferers that enable them to have healthy lives.

The Challenge

The major obstacles Allergopharma experienced in the process of seeking the research allowance include:

• Insufficient knowledge of the Forschungszulage programme: The knowledge Allergopharma had about the research allowance programme was limited and did not suffice to analyse the R&D projects in order to determine whether they would qualify and to proceed with the claim.

• Limited internal capacity: The internal team of Allergopharma lacked the resources and time to understand the research allowance, prepare the required documents, and submit the application without the support of a knowledgeable external team.

• Lack of awareness about retroactive applications: Despite having a recently completed eligible R&D project, Allergopharma could not leverage the financial support that the project could obtain due to limited knowledge about the opportunity to submit a retroactive application.

The Solution

Allergopharma collaborated with innoscripta to navigate the research allowance process. innoscripta supported them with project consultation and with a software platform tailored for R&D project management. How Allergopharma overcame obstacles and met the defined objective of acquiring the research allowance with innoscripta is described in detail as follows.

• Use of innoscripta’s software platform: “The software from innoscripta helps us keep track of our projects. At any time, we can see where we stand and which projects have been submitted.”

innoscripta's project management software tool enabled Allergopharma to manage and track all information about the different R&D projects. It also helped them to track the submitted research allowance application and its phases.

• Expert assessment and documentation support: “In addition, they bring highly valuable experience and can assess very well whether an application is likely to be successful.”

With extensive knowledge and experience in research allowance and innovation consulting, innoscripta's team supported Allergopharma in carefully assessing both, ongoing and recently ended projects that might be eligible for the research allowance claim. They provided strategic feedback on the ways to strengthen the applications and to ensure compliance with the statutory requirements.

The Impact

The values innoscripta was able to generate for Allergopharma go beyond successfully acquiring the financial support to the point of optimising their internal processes.

• Successfully leveraging R&D costs: Partnering with innoscripta allowed Allergopharma to convert their R&D expenses into financial support for R&D projects through the research allowance

• Enhanced internal processes and project control: Working with innoscripta led to notable optimisation of internal workflows in terms of R&D project management at Allergopharma. In addition, innoscripta's software brought greater visibility into project management and research allowance processes that resulted in better coordination between departments.

Conclusion

Christine Marquardt highlights innoscripta’s professionalism, reliability, technical understanding of clinical studies and pharmaceutical development. She concludes with a strong recommendation of innoscripta without any reservations for companies undertaking R&D projects.”